References

Chappell LC, Chambers J, Dixon PH Ursodeoxycholic acid versus placebo in the treatment of women with intrahepatic cholestasis of pregnancy (ICP) to improve perinatal outcomes: protocol for a randomised controlled trial (PITCHES). Trials. 2018; 19:(1)

Dixon PH, Sambrotta M, Chambers J An expanded role for heterozygous mutations of ABCB4, ABCB11, ATP8B1, ABCC2 and TJP2 in intrahepatic cholestasis of pregnancy. Sci Rep.. 2017; 7

Dixon PH, Williamson C. The molecular genetics of intrahepatic cholestasis of pregnancy. Obstet Med. 2008; 1:65-71

Geenes VL, Lim YH, Bowman N A placental phenotype for intrahepatic cholestasis of pregnancy. Placenta. 2011; 32:(12)1026-32

Geenes V, Williamson C, Chappell LC. Intrahepatic cholestasis of pregnancy. Obstet Gynecol.. 2016; 18:(4)273-81

Gorelik J, Shevchuk AI, Diakonov I Dexamethasone and ursodeoxycholic acid protect against the arrhythmogenic effect of taurocholate in an in vitro study of rat cardiomyocytes. BJOG.. 2003; 110:467-74

Marschall HU. Management of intrahepatic cholestasis of pregnancy. Expert Rev Gastroenterol Hepatol. 2015; 9:(10)1273-9

Miragoli M, Sheikh Abdul Kadir SH, Sheppard MN A protective antiarrhythmic role of ursodeoxycholic acid in an in vitro rat model of the cholestatic fetal heart. Hepatology. 2011; 54:(4)1282-92

Ovadia C, Williamson C. Intrahepatic cholestasis of pregnancy: recent advances. Clin Dermatol.. 2016; 34:327-34

Ovadia C, Seed PT, Sklavounos A Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. Lancet. 2019; 393:(10174)899-909

Papacleovoulou G, Abu-Hayyeh S, Nikolopoulou E Maternal cholestasis during pregnancy programs metabolic disease in offspring. J Clin Invest.. 2013; 23:3172-81

Obstetric Cholestasis [Green-top Guideline 43].London: RCOG; 2011

Wikström Shemer EA, Stephansson O, Thuresson M, Thorsell M, Ludvigsson JF, Marschall HU. Intrahepatic cholestasis of pregnancy and cancer, immune-mediated and cardiovascular diseases: a population-based cohort study. J Hepatol.. 2015; 63:(2)456-61

Williamson C, Geenes V. Intrahepatic cholestasis of pregnancy. Obstet Gynecol.. 2014; 124:(1)120-33

Ask, ‘could it be ICP?’

02 September 2019
6 min read
Volume 27 · Issue 9

Abstract

Intrahepatic cholestasis of pregnancy (ICP) is a condition that can have devastating consequences for women and babies. Jenny Chambers explains what ICP is and how it can be managed

ICP Support started life as a support and information line in 1991. In the way many charities begin, it evolved out of personal tragedy. In my case, that tragedy was two stillbirths and the diagnosis of a liver condition of pregnancy called intrahepatic cholestasis of pregnancy (ICP), which less than a handful of health professionals in the UK knew about at the time.

When I learnt why my two daughters had died and that women were advised that itching (the predominant symptom in ICP) in pregnancy was normal, I felt a huge obligation to raise awareness among women and health professionals. Back then, knowledge of the condition was relatively scant; it was generally thought that delivering the baby by 38 weeks of pregnancy (an idea fuelled by research in Australia in the 1980s) to avoid stillbirth was all that was needed. I thought my task would be simple and quick: raise awareness, help change practice so that unborn babies were delivered by 38 weeks', support women until obstetric practices changed, then get back to a ‘normal’ life.

Register now to continue reading

Thank you for visiting British Journal of Midwifery and reading some of our peer-reviewed resources for midwives. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to our clinical or professional articles

  • Unlimited access to the latest news, blogs and video content

  • Monthly email newsletter